SCHEMBL280123

SCHEMBL280123

Cc1ccc(C(=O)CCCC(=O)O)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.55
POLB P06746 4/20 0.51
TDP1 Q9NUW8 2/20 0.51
KMT2A Q03164 2/20 0.51
HPGD P15428 2/20 0.47
ALDH1A1 P00352 3/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
LMNA P02545 1/20 0.44
PRNP P04156 1/20 0.44
RECQL P46063 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
PDE4B Q07343 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
USP2 O75604 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22721115 0.93 DAO (0.57) DAOPOLBTDP1KMT2AHPGD
SCHEMBL279619 0.89 DAO (0.59) DAOPOLBTDP1KMT2AHPGD
SCHEMBL15979700 0.85 DAO (0.61) DAOPOLBTDP1KMT2AHPGD
SCHEMBL10972012 0.82 DAO (0.50) DAOPOLBTDP1KMT2AHPGD
SCHEMBL9378748 0.82 DAO (0.50) DAOPOLBTDP1KMT2AHPGD
SCHEMBL24721882 0.79 DAO (0.55) DAOPOLBTDP1KMT2AHPGD
SCHEMBL6975607 0.79 DAO (0.61) DAOPOLBTDP1KMT2AHPGD
SCHEMBL280053 0.78 DAO (0.46) DAOPOLBTDP1KMT2AHPGD
SCHEMBL5866598 0.78 DAO (0.53) DAOPOLBTDP1KMT2AHPGD
SCHEMBL10471221 0.77 DAO (0.53) DAOPOLBTDP1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL DAO 1673/4885POLB 4352/4885TDP1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.